Genelux Corp GNLX IPO will take place January, 26 on the NASDAQ exchange under the ticker GNLX.
The company is offering shares at an expected price between $6.00 and $7.00 per share with an insider lock-up period of 180 days ending on July 25, 2023.
See also: Benzinga IPO Calendar
About Genelux Corp
Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
See also: Benzinga's Most Shorted Stocks
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.